Anjali N Patel1, Seonjoo Lee1, Howard F Andrews1, Gregory H Pelton1, Susan K Schultz1, David L Sultzer1, Jacobo Mintzer1, Danilo de la Pena1, Sanjay Gupta1, Sylvia Colon1, Corbett Schimming1, Bruce Levin1, D P Devanand1. 1. From the Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York; the Gertrude H. Sergievsky Center and the Department of Neurology, College of Physicians and Surgeons, Columbia University, and the Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Columbia University, New York; the Department of Biostatistics, Mailman School of Public Health, Columbia University, New York; the Division of Translational Research, Department of Neuroscience, Medical University of South Carolina, and the Ralph H. Johnson VA Medical Center, Charleston; the Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City; the Clinical Biotechnology Research Institute, Roper St. Francis Healthcare, Charleston; the Research Center for Clinical Studies, Norwalk, Conn.; the Department of Psychiatry, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo; the Department of Psychiatry, VA Medical Center, Tuscaloosa, Ala.; and the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
Abstract
OBJECTIVE: In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse. METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated withrisperidonefor 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks. As reported previously, discontinuation of risperidone was associated with a two- to fourfold increased risk of relapse over 16-32 weeks. In planned post hoc analyses, the authors examined associations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization. RESULTS: Compared with patients with mild hallucinations or no hallucinations, patients with severe hallucinations as a presenting symptom at baseline had a higher likelihood of relapse (hazard ratio=2.96, 95% CI=1.52, 5.76). This effect was present for the subgroup with auditory hallucinations, but not the subgroup with visual hallucinations. Among patients with baseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who continued risperidone (p<0.02). This group difference remained significant for severe (77.8%) compared with mild (36%) hallucinations. NPI domain scores after the initial open-treatment phase were not associated with relapse. CONCLUSIONS: Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment. For patients with hallucinations, particularly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because of high relapse risk.
RCT Entities:
OBJECTIVE: In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse. METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks. As reported previously, discontinuation of risperidone was associated with a two- to fourfold increased risk of relapse over 16-32 weeks. In planned post hoc analyses, the authors examined associations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization. RESULTS: Compared with patients with mild hallucinations or no hallucinations, patients with severe hallucinations as a presenting symptom at baseline had a higher likelihood of relapse (hazard ratio=2.96, 95% CI=1.52, 5.76). This effect was present for the subgroup with auditory hallucinations, but not the subgroup with visual hallucinations. Among patients with baseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who continued risperidone (p<0.02). This group difference remained significant for severe (77.8%) compared with mild (36%) hallucinations. NPI domain scores after the initial open-treatment phase were not associated with relapse. CONCLUSIONS:Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment. For patients with hallucinations, particularly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because of high relapse risk.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: D P Devanand; D M Jacobs; M X Tang; C Del Castillo-Castaneda; M Sano; K Marder; K Bell; F W Bylsma; J Brandt; M Albert; Y Stern Journal: Arch Gen Psychiatry Date: 1997-03
Authors: D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: Clive G Ballard; Alan Thomas; Jane Fossey; Lesley Lee; Robin Jacoby; Marisa M Lana; Carol Bannister; Rupert McShane; Alan Swann; Ed Juszczak; John T O'Brien Journal: J Clin Psychiatry Date: 2004-01 Impact factor: 4.384
Authors: Dilip V Jeste; Dan Blazer; Daniel Casey; Thomas Meeks; Carl Salzman; Lon Schneider; Pierre Tariot; Kristine Yaffe Journal: Neuropsychopharmacology Date: 2007-07-18 Impact factor: 7.853
Authors: Frédéric Blanc; Vincent Noblet; Nathalie Philippi; Benjamin Cretin; Jack Foucher; Jean-Paul Armspach; François Rousseau Journal: PLoS One Date: 2014-12-05 Impact factor: 3.240
Authors: Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong Journal: Neurosci Lett Date: 2019-04-01 Impact factor: 3.046
Authors: Ellen Van Leeuwen; Mirko Petrovic; Mieke L van Driel; An Im De Sutter; Robert Vander Stichele; Tom Declercq; Thierry Christiaens Journal: Cochrane Database Syst Rev Date: 2018-03-30